Stock Track | TENNOR THERAP-B Soars 105.55% on IPO Debut Amid Heavy Oversubscription and Promising Drug Pipeline

Stock Track05-22 09:40

TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a Friday.

The surge follows the company's highly anticipated initial public offering debut on the Hong Kong Stock Exchange. Investor demand was exceptionally strong, with the Hong Kong public offer being oversubscribed by 9,015.11 times and the international offering oversubscribed by 9.24 times. The IPO raised net proceeds of approximately HK$598 million, with cornerstone investments from reputable firms including AMR Action Fund, Hua Yuan International, and Orient Asset Management.

Market enthusiasm is driven by TenNor Therapeutics' promising pipeline of innovative drugs targeting bacterial infections. The company's core product, TNP-2198 (Lifotinezole), represents the first new molecular entity candidate globally targeting Helicobacter pylori infection since its discovery in 1982, with a New Drug Application submitted to Chinese regulators and expected approval by the end of 2026. Another key candidate, TNP-2092 injection (Lifotinezole), targets implant-related bacterial infections and is the world's first new molecular entity with potential efficacy against biofilm infections at clinically achievable doses.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183117616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183117616","market":"us","top_or_hot":-1,"title":"Stock Track | TENNOR THERAP-B Soars 105.55% on IPO Debut Amid Heavy Oversubscription and Promising Drug Pipeline","media":"Stock Track","content":"<p>TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a Friday.</p><p>The surge follows the company's highly anticipated initial public offering debut on the Hong Kong Stock Exchange. Investor demand was exceptionally strong, with the Hong Kong public offer being oversubscribed by 9,015.11 times and the international offering oversubscribed by 9.24 times. The IPO raised net proceeds of approximately HK$598 million, with cornerstone investments from reputable firms including AMR Action Fund, Hua Yuan International, and Orient Asset Management.</p><p>Market enthusiasm is driven by TenNor Therapeutics' promising pipeline of innovative drugs targeting bacterial infections. The company's core product, TNP-2198 (Lifotinezole), represents the first new molecular entity candidate globally targeting Helicobacter pylori infection since its discovery in 1982, with a New Drug Application submitted to Chinese regulators and expected approval by the end of 2026. Another key candidate, TNP-2092 injection (Lifotinezole), targets implant-related bacterial infections and is the world's first new molecular entity with potential efficacy against biofilm infections at clinically achievable doses.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TENNOR THERAP-B Soars 105.55% on IPO Debut Amid Heavy Oversubscription and Promising Drug Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TENNOR THERAP-B Soars 105.55% on IPO Debut Amid Heavy Oversubscription and Promising Drug Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-22 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a Friday.</p><p>The surge follows the company's highly anticipated initial public offering debut on the Hong Kong Stock Exchange. Investor demand was exceptionally strong, with the Hong Kong public offer being oversubscribed by 9,015.11 times and the international offering oversubscribed by 9.24 times. The IPO raised net proceeds of approximately HK$598 million, with cornerstone investments from reputable firms including AMR Action Fund, Hua Yuan International, and Orient Asset Management.</p><p>Market enthusiasm is driven by TenNor Therapeutics' promising pipeline of innovative drugs targeting bacterial infections. The company's core product, TNP-2198 (Lifotinezole), represents the first new molecular entity candidate globally targeting Helicobacter pylori infection since its discovery in 1982, with a New Drug Application submitted to Chinese regulators and expected approval by the end of 2026. Another key candidate, TNP-2092 injection (Lifotinezole), targets implant-related bacterial infections and is the world's first new molecular entity with potential efficacy against biofilm infections at clinically achievable doses.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1183117616","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183117616","pubTimestamp":1779414002,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"个股赛道|Tennor Therap-B IPO首秀飙升105.55%，超额认购严重，药物管线前景看好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TENNOR THERAP-B (06872) experienced a soaring movement intraday, with its stock price increasing by 105.55%. This significant price movement occurred during the morning trading session on a Friday.The surge follows the company's highly anticipated initial public offering debut on the Hong Kong Stock Exchange. Investor demand was exceptionally strong, with the Hong Kong public offer being oversubscribed by 9,015.11 times and the international offering oversubscribed by 9.24 times. The IPO raised net proceeds of approximately HK$598 million, with cornerstone investments from reputable firms including AMR Action Fund, Hua Yuan International, and Orient Asset Management.Market enthusiasm is driven by TenNor Therapeutics' promising pipeline of innovative drugs targeting bacterial infections. The company's core product, TNP-2198 (Lifotinezole), represents the first new molecular entity candidate globally targeting Helicobacter pylori infection since its discovery in 1982, with a New Drug Application submitted to Chinese regulators and expected approval by the end of 2026. Another key candidate, TNP-2092 injection (Lifotinezole), targets implant-related bacterial infections and is the world's first new molecular entity with potential efficacy against biofilm infections at clinically achievable doses.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183117616","isCrawlerRequest":true}